title: [Safety and effectiveness of tumor-ablative chemotherapy combined with low intensity modified conditioning regimen for 30 patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation].
abstract: This study was aimed to investigate the safety and effectiveness of tumor-ablative Chemotherapy combined with low intensity conditioning regiment BUCy/TBICy for patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical data of 30 patients with hematologic malignancies received above-mentioned therapeutic method from January 2012 to January 2013 was analyzed retrospectively, and the engraftment, GVHD, infection, conditioning-related toxicity, relapse and survival rates were evaluated. All the patients signed the informed consent before transplantation. The median follow-up duration was 20.5 (16.3-27.3) months. The results indicated that all the patients had been engrafted successfully. One year overall survival (OS) and disease-free survival (DFS) rates were 93.3% and 83.3% respectively. No conditioning-related toxicity occurred. The incidences of II-IV grade aGVHD was 37.9%, among which incidence of III-IV grade aGVHD was 3.4%; incidence of extensive cGVHD was 13.8%. So far, 1 case relapsed, 1 case displayed graft rejection, and poor function of graft occurred in 1 case, death occurred in 2 cases(6.7%). It is concluded that tumor-ablative chemotherapy combined with low intensity-modified BUCy/TBICy is safe and effective in allogeneic hematopoietic stem cell transplantation for hematologic malignancies, and it is useful to reduce relapse of hematologic malignancies after transplantation.
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Rong-Mu
authors.initials: RM
authors.lastname: Luo
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: Dwanming@hotmail.com.
authors.forename: Wan-ming
authors.initials: WM
authors.lastname: Da
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Hu
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Ying-Jian
authors.initials: YJ
authors.lastname: Si
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Xiao-Mei
authors.initials: XM
authors.lastname: Zhang
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Zhen-Lan
authors.initials: ZL
authors.lastname: Du
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Quan-Hua
authors.initials: QH
authors.lastname: Liu
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Ya
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Yue
authors.affiliation: Department of Cell therapy, The General Hospital of Beijing Military Command, Beijing 100700, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult